Last Updated: May 10, 2026

Suppliers and packagers for cystaran


✉ Email this page to a colleague

« Back to Dashboard


cystaran

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Leadiant Biosci Inc CYSTARAN cysteamine hydrochloride SOLUTION/DROPS;OPHTHALMIC 200740 NDA Leadiant Biosciences, Inc. 54482-020-02 15 mL in 1 BOTTLE (54482-020-02) 2012-12-30
Leadiant Biosci Inc CYSTARAN cysteamine hydrochloride SOLUTION/DROPS;OPHTHALMIC 200740 NDA Leadiant Biosciences, Inc. 54482-035-02 15 mL in 1 BOTTLE (54482-035-02) 2012-12-30
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

CYSTARAN (Drug Product) — Supplier Landscape

Last updated: April 27, 2026

What suppliers make up the CYSTARAN supply chain?

No complete, supplier-level evidence is available in the provided material to identify the specific manufacturing, fill-finish, API, or packaging suppliers for the drug product “CYSTARAN” as a named commercial product.

Because a supplier list without verified attribution would be incomplete and inaccurate, no supplier names are provided.

Who supplies the API, contract manufacturing, and packaging for CYSTARAN?

No verified records are provided that map “CYSTARAN” to:

  • API manufacturer(s) (by controlled substance, intermediate, or final API name)
  • drug product manufacturer(s) (CMO/CDMO)
  • fill-finish site(s)
  • packaging supplier(s) (primary and secondary packaging)

Which filings or registries identify CYSTARAN suppliers?

No citations, regulatory dossiers, labels, master files, or procurement records are provided that would support supplier identification for:

  • FDA Orange Book product listings
  • EMA EPAR/PL (if applicable)
  • local medicines registers
  • DMF/EDQM data
  • GMP inspection databases tied to product name “CYSTARAN”

What verified supplier candidates can be listed from CYSTARAN evidence?

None. No supplier candidates can be listed with proof.

How should CYSTARAN supplier diligence be structured (based on what evidence typically determines suppliers)?

No supplier evidence is present to tie CYSTARAN to a particular dossier trail. The only defensible approach in an evidence-driven patent and R&D diligence setting is to use dossier-linked or label-linked proof, but the necessary source artifacts are not included here.


Key Takeaways

  • Supplier identification for “CYSTARAN” cannot be produced from the provided inputs without introducing inaccuracies.
  • No validated sources are present that connect the product name “CYSTARAN” to API, manufacturing, fill-finish, or packaging suppliers.
  • A supplier list for CYSTARAN requires label, registration, dossier, or inspection-linked documentation, none of which is included here.

FAQs

  1. Can you list API suppliers for CYSTARAN from the information provided?
    No. No verified supplier evidence is provided.

  2. Can you list contract manufacturing or fill-finish suppliers for CYSTARAN?
    No. No validated manufacturing or site evidence is provided.

  3. Do you have packaging supplier details for CYSTARAN?
    No. No primary or secondary packaging supplier evidence is provided.

  4. Which regulatory databases typically show CYSTARAN supplier details?
    Product listings, EPAR/PL, DMF/MAH-linked dossier records, and GMP inspection records are the usual sources, but no sources are included here.

  5. What minimum evidence is needed to name CYSTARAN suppliers correctly?
    Label, product registration dossiers, DMF/ASMF references, or inspection-linked records that explicitly connect supplier identity to the CYSTARAN product.


References

[1] No sources were provided in the prompt.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.